Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers

Bibliography

• LEVY BI: How to explain the differences between renin angiotensin system modulators. Am. J. Hypertens. (2005) 18(9 Pt 2):134S-141S.
   Web of Science ®Google Scholar
• HABER E: Peptide inhibitors of renin in cardiovascular studies. Fed. Proc. (1983) 42(15):3155-3161.
   PubMedGoogle Scholar
• AZIZI M, WEBB R, NUSSBERGER J, HOLLENBERG NK: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. (2006) 24(2):243-256.
   PubMed Web of Science ®Google Scholar
• ONDETTI MA, RUBIN B, CUSHMAN DW: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally-active antihypertensive agents. Science (1977) 196(4288):441-444.
   PubMed Web of Science ®Google Scholar
• MARTIN J, KRUM H: Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacol. Res. (2002) 46(3):203-212.
   PubMed Web of Science ®Google Scholar
• WOOD JM, MAIBAUM J, RAHUEL J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. (2003) 308(4):698-705.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342(3):145-153.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. (1992) 327(10):669-677.
   PubMed Web of Science ®Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. (1995) 333(25):1670-1676.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. (1993) 329(20):1456-1462.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345(12):861-869.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, GHERARDI G et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 354(9176):359-364.
   PubMed Web of Science ®Google Scholar
• DILLON JJ: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin. Nephrol. (2004) 24(3):218-224.
   PubMed Web of Science ®Google Scholar
• CORVOL P, WILLIAMS TA, SOUBRIER F: Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol. (1995) 248:283-305.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, BRADSTREET TE, MCWILLIAMS EJ et al.: Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension (1995) 25(1):37-46.
   PubMed Web of Science ®Google Scholar
• MASCHIO G, ALBERTI D, JANIN G et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. (1996) 334(15):939-945.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, WEIR MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. (2000) 160(5):685-693.
   PubMed Web of Science ®Google Scholar
• PRESTON RA, BALTODANO NM, ALONSO AB, EPSTEIN M: Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J. Clin. Pharmacol. (2002) 42(7):754-761.
   PubMed Web of Science ®Google Scholar
• EVANS KJ, GREENBERG A: Hyperkalemia: a review. J. Intensive Care Med. (2005) 20(5):272-290.
   PubMedGoogle Scholar
• REARDON LC, MACPHERSON DS: Hyperkalemia in out-patients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch. Intern. Med. (1998) 158(1):26-32.
   PubMed Web of Science ®Google Scholar
• SPEIRS CJ, DOLLERY CT, INMAN WH, RAWSON NS, WILTON LV: Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure. BMJ (1988) 297(6652):830-832.
   PubMed Web of Science ®Google Scholar
• JUURLINK DN, MAMDANI M, KOPP A, LAUPACIS A, REDELMEIER DA: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA (2003) 289(13):1652-1658.
   PubMed Web of Science ®Google Scholar
• CHENG HF, HARRIS RC: Renal effects of non-steroidal anti-inflammatory drugs and selective COX-2 inhibitors. Curr. Pharm. Des. (2005) 11(14):1795-1804
   PubMed Web of Science ®Google Scholar
• HART D, LIFSCHITZ MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am. J. Nephrol. (1987) 7(5):408-418.
   PubMed Web of Science ®Google Scholar
• KURATA C, UEHARA A, SUGI T, YAMAZAKI K: Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors. Jpn. Circ. J. (1999) 63(12):1002-1003.
   PubMedGoogle Scholar
• HAY E, DERAZON H, BUKISH N, KATZ L, KRUGLYAKOV I, ARMONI M: Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J. Emerg. Med. (2002) 22(4):349-352.
   PubMed Web of Science ®Google Scholar
• KAPLAN B, WANG Z, ABECASSIS MM, FRYER JP, STUART FP, KAUFMAN DB: Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation (1996) 62(8):1174-1175
   PubMed Web of Science ®Google Scholar
• MARTINEZ-CASTELAO A, HUESO M, SANZ V, REJAS J, ALSINA J, GRINYO JM: Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int. Suppl. (1998) 68:S130-S134.
   PubMedGoogle Scholar
• SCHMIDT A, GRUBER U, BOHMIG G, KOLLER E, MAYER G: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol. Dial. Transplant. (2001) 16(5):1034-1037.
   PubMed Web of Science ®Google Scholar
• JORDE UP: Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact. Cardiol. Rev. (2006) 14(2):81-87.
   PubMedGoogle Scholar
• NASSIACOS D, MELONI S: [Tolerability and efficacy of aldosterone inhibition with canrenone in heart failure: the real-world experience of an out-patient heart failure clinic]. Ital. Heart J. (2005) 6(Suppl. 1):51S-65S.
   Google Scholar
• OSTER JR, SINGER I, FISHMAN LM: Heparin-induced aldosterone suppression and hyperkalemia. Am. J. Med. (1995) 98(6):575-586.
   PubMed Web of Science ®Google Scholar
• PERAZELLA MA, BISWAS P: Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am. J. Kidney Dis. (1999) 33(4):782-785.
   PubMed Web of Science ®Google Scholar
• MARTYN JA, RICHTSFELD M: Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology (2006) 104(1):158-169.
   PubMed Web of Science ®Google Scholar
• PERAZELLA MA: Drug-induced hyperkalemia: old culprits and new offenders. Am. J. Med. (2000) 109(4):307-14.
   PubMed Web of Science ®Google Scholar
• AHUJA TS, FREEMAN D Jr, MAHNKEN JD, AGRAHARKAR M, SIDDIQUI M, MEMON A: Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am. J. Nephrol. (2000) 20(4):268-272.
   PubMed Web of Science ®Google Scholar
• ACKER CG, JOHNSON JP, PALEVSKY PM, GREENBERG A: Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch. Intern. Med. (1998) 158(8):917-924.
   PubMed Web of Science ®Google Scholar
• RAEBEL MA, MCCLURE DL, SIMON SR et al.: Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol. Drug Saf. (2006) Epub ahead of print.
   Google Scholar
• PALMER BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N. Engl. J. Med. (2004) 351(6):585-592.
   PubMed Web of Science ®Google Scholar
• HEBERT LA: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. (2006) 354(2):189-191.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360(9335):752-760.
   PubMed Web of Science ®Google Scholar
• HANNEDOUCHE T, GODIN M, FRIES D, FILLASTRE JP: Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron (1991) 57(2):230-231.
   PubMedGoogle Scholar
• REMME WJ: Hypotension after first-dose ACE inhibitor administration in heart failure-should doctors stop worrying? Cardiovasc. Drugs Ther. (2001) 15(6):475-477.
   Google Scholar
• VITOVEC J, SPINAR J: Heart failure and first dose hypotension after angiotensin-converting enzyme inhibitors. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. (2004) 148(2):113-118.
   PubMedGoogle Scholar
• HOBBS FD, JONES MI, ALLAN TF, WILSON S, TOBIAS R: European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur. Heart J. (2000) 21(22):1877-1887.
   PubMed Web of Science ®Google Scholar
• LINDGREN BR, GRUNDSTROM N, ANDERSSON RG: Effects of an alpha-2 adrenoceptor agonist on angiotensin-converting enzyme inhibitor-induced hypotension and potentiated allergen-evoked inflammatory skin responses. J. Pharmacol. Exp. Ther. (1988) 245(3):932-935.
   PubMed Web of Science ®Google Scholar
• KAO CD, CHANG JB, CHEN JT, WU ZA, SHAN DE, LIAO KK: Hypotension due to interaction between lisinopril and tizanidine. Ann. Pharmacother. (2004) 38(11):1840-1843.
   PubMed Web of Science ®Google Scholar
• MACFADYEN RJ, LEES KR, REID JL: Differences in first dose response to angiotensin-converting enzyme inhibition in congestive heart failure: a placebo-controlled study. Br. Heart J. (1991) 66(3):206-211.
   PubMedGoogle Scholar
• CORIAT P, RICHER C, DOURAKI T et al.: Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology (1994) 81(2):299-307.
   PubMed Web of Science ®Google Scholar
• COMFERE T, SPRUNG J, KUMAR MM et al.: Angiotensin system inhibitors in a general surgical population. Anesth. Analg. (2005) 100(3):636-644.
   PubMed Web of Science ®Google Scholar
• ANDERSON S, RENNKE HG, BRENNER BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. (1992) 41(4):891-897.
   PubMed Web of Science ®Google Scholar
• PALMER BF: Renal dysfunction complicating the treatment of hypertension. N. Engl. J. Med. (2002) 347(16):1256-1261.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349(9054):747-752.
   PubMed Web of Science ®Google Scholar
• KEANE WF, ANDERSON S, AURELL M, DE ZEEUW D, NARINS RG, POVAR G: Angiotensin-converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann. Intern. Med. (1989) 111(6):503-516.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, BENINI R et al.: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. (1999) 10(5):997-1006.
   PubMed Web of Science ®Google Scholar
• WRIGHT JT Jr, BAKRIS G, GREENE T et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 288(19):2421-2431.
   PubMed Web of Science ®Google Scholar
• APPERLOO AJ, DE ZEEUW D, DE JONG PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. (1997) 51(3):793-797.
   PubMed Web of Science ®Google Scholar
• IHLE BU, WHITWORTH JA, SHAHINFAR S et al.: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am. J. Kidney Dis. (1996) 27(4):489-495
   PubMed Web of Science ®Google Scholar
• HOU FF, ZHANG X, ZHANG GH et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. (2006) 354(2):131-140.
   PubMed Web of Science ®Google Scholar
• SHLIPAK MG: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. (2003) 138(11):917-924.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, FARDET L, LAUNAY-VACHER, DORENT R, PETITCLERC T, DERAY G: Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin. Pharmacol. Ther. (2002) 71(6):503-507.
   PubMed Web of Science ®Google Scholar
• KAMPER AL, NIELSEN OJ: Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand. J. Clin. Lab. Invest. (1990) 50(6):611-618.
   PubMed Web of Science ®Google Scholar
• MATSUMURA M, NOMURA H, KONI I et al.: Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in haemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. Nephron (1997) 77(2):164-168.
   PubMedGoogle Scholar
• HUBERT C, SAVARY K, GASC JM, CORVOL P: The hematopoietic system: a new niche for the renin-angiotensin system. Nat. Clin. Pract. Cardiovasc. Med. (2006) 3(2):80-85.
   PubMedGoogle Scholar
• QUAN A: Fetopathy associated with exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum. Dev. (2006) 82(1):23-28.
   PubMed Web of Science ®Google Scholar
• ESTHER CR Jr, HOWARD TE, MARINO EM, GODDARD JM, CAPECCHI MR, BERNSTEIN KE: Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab. Invest. (1996) 74(5):953-965.
   PubMed Web of Science ®Google Scholar
• KREGE JH, JOHN SW, LANGENBACH LL et al.: Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature (1995) 375(6527):146-148.
   PubMed Web of Science ®Google Scholar
• KONDOH G, TOJO H, NAKATANI Y et al.: Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat. Med. (2005) 11(2):160-166.
   PubMed Web of Science ®Google Scholar
• COOPER WO, HERNANDEZ-DIAZ S, ARBOGAST PG et al.: Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. (2006) 354(23):2443-2451.
   PubMed Web of Science ®Google Scholar
• ALWAN S, POLIFKA JE, FRIEDMAN JM: Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res. A. Clin. Mol. Teratol. (2005) 73(2):123-130.
   PubMed Web of Science ®Google Scholar
• RATNAPALAN S, KOREN G: Taking ACE inhibitors during pregnancy. Is it safe? Can. Fam. Physician (2002) 48:1047-1049.
   PubMed Web of Science ®Google Scholar
• SHRIM A, BERGER H, KINGDOM J, HAMOUDI A, SHAH PS, KOREN G: Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible. Can. Fam. Physician (2005) 51:1335-1337.
   PubMed Web of Science ®Google Scholar
• DICPINIGAITIS PV: Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest (2006) 129(1 Suppl.):169S-173S.
   Web of Science ®Google Scholar
• KARAGIANNIS A, PYRPASOPOULOU A, TZIOMALOS K, FLORENTIN M, ATHYROS V: Angioedema may not be a class side effect of the angiotensin-converting-enzyme inhibitors. QJM (2006) 99(3):197-198.
   PubMed Web of Science ®Google Scholar
• IRONS BK, KUMAR A: Valsartan-induced angioedema. Ann. Pharmacother. (2003) 37(7-8):1024-1027.
   PubMed Web of Science ®Google Scholar
• WOOD JM, STANTON JL, HOFBAUER KG: Inhibitors of renin as potential therapeutic agents. J. Enzyme Inhib. (1987) 1(3):169-185.
   PubMedGoogle Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally-active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39(1):E1-E8.
   PubMed Web of Science ®Google Scholar
• PILZ B, SHAGDARSUREN E, WELLNER M et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46(3):569-576.
   PubMed Web of Science ®Google Scholar
• DELABAYS A, NUSSBERGER J, PORCHET M et al.: Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (1989) 13(6 Pt 2):941-947.
   PubMed Web of Science ®Google Scholar
• WOOD JM, CRISCIONE L, DE GASPARO M et al.: CGP 38 560: orally-active, low-molecular-weight renin inhibitor with high potency and specificity. J. Cardiovasc. Pharmacol. (1989) 14(2):221-226.
   PubMed Web of Science ®Google Scholar
• KOBRIN I, VISKOPER RJ, LASZT A, BOCK J, WEBER C, CHARLON V: Effects of an orally-active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am. J. Hypertens. (1993) 6(5 Pt 1):349-356.
   PubMed Web of Science ®Google Scholar
• MENARD J, BOGER RS, MOYSE DM, GUYENE TT, GLASSMAN HN, KLEINERT HD: Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation (1995) 91(2):330-338.
   PubMed Web of Science ®Google Scholar
• FISCHLI W, CLOZEL JP, BREU V et al.: Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension (1994) 24(2):163-169.
   PubMed Web of Science ®Google Scholar
• HOOVER DJ, LEFKER BA, ROSATI RL et al.: Discovery of inhibitors of human renin with high oral bioavailability. Adv. Exp. Med. Biol. (1995) 362:167-180.
   PubMedGoogle Scholar
• OGIHARA T, NAGANO M, HIGAKI J et al.: Antihypertensive efficacy of FK906, a novel human renin inhibitor. Clin. Ther. (1993) 15(3):539-548.
   PubMed Web of Science ®Google Scholar
• WESSALE JL, CALZADILLA SV, BOYD SA et al.: Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs. J. Cardiovasc. Pharmacol. (1993) 22(4):644-652.
   PubMed Web of Science ®Google Scholar
• FISHER ND, HOLLENBERG NK: Is there a future for renin inhibitors? Expert Opin. Investig. Drugs (2001) 10(3):417-426.
   PubMed Web of Science ®Google Scholar
• STANTON A: Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs (2003) 3(6):389-394.
   PubMedGoogle Scholar
• DIETERLE W, CORYNEN S, VAIDYANATHAN S, MANN J: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmacol. Ther. (2005) 43(11):527-535.
   PubMed Web of Science ®Google Scholar
• AZIZI M, MENARD J, BISSERY A et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. (2004) 15(12):3126-3133.
   PubMed Web of Science ®Google Scholar
• STANTON A, JENSEN C, NUSSBERGER J, O’BRIEN E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42(6):1137-1143.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK, FISHER ND: Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension (1995) 26(4):602-609.
   PubMed Web of Science ®Google Scholar
• VAN PAASSEN P, DE ZEEUW D, NAVIS G, DE JONG PE: Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol. Dial. Transplant. (2000) 15(5):637-643.
   PubMed Web of Science ®Google Scholar
• VAN PAASSEN P, NAVIS GJ, DE JONG PE, DE ZEEUW D: Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. Eur. J. Clin. Invest. (1999) 29(12):1019-1026.
   PubMed Web of Science ®Google Scholar
• MENARD J, GUYENE TT, PEYRARD S, AZIZI M: Conformational changes in prorenin during renin inhibition in vitro and in vivo. J. Hypertens. (2006) 24(3):529-534.
   PubMed Web of Science ®Google Scholar
• FISHER ND, HOLLENBERG NK: Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. (2005) 16(3):592-599.
   PubMed Web of Science ®Google Scholar